ACM
IOVA icon

Aster Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Aster Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,008
Closed -$3.36K – 1050
2026
Q1 		$3.36K Buy
1,008
+983
+3,932% +$3.14K ﹤0.01% 716
2025
Q4 		$68 Buy
+25
New +$58 ﹤0.01% 1047
2025
Q2 		– Sell
-754
Closed -$3.19K – 1301
2025
Q1 		$3.19K Buy
+754
New +$3.89K ﹤0.01% 1153

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Aster Capital Management's IOVA Position: Q2 2026 in Review

Aster Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 1,008 shares — an estimated $3.36K sold.

Aster Capital Management first reported a position in IOVA in Q1 2025 and held it in 3 quarters. The position peaked at $3.36K in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Aster Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 1,008 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.36K.
  • Aster Capital Management first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 3 quarters.
  • Aster Capital Management's Iovance Biotherapeutics position peaked at $3.36K in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.